Skip to main content
. 2022 Feb 14;11:744161. doi: 10.3389/fonc.2021.744161

Table 3.

Ongoing RCTs on efficacy of neoadjuvant chemotherapy.

Trial Resectability Number of patients Treatment arms Status
NEONAX (48) R 166 Gemcitabine/Nab-paclitaxel + Surgery + adjuvant Gemcitabine/Nab-paclitaxel versus Surgery + adjuvant Gemcitabine/Nab-paclitaxel Recruiting
NEOPAC (47) R 310 Gemcitabine + Oxaliplatin + Surgery + adjuvant Gemcitabine versus Surgery + adjuvant Gemcitabine Completed
NORPACT-1 (49) R 90 FOLFIRINOX + Surgery + adjuvant Gemcitabine/Capecitabine versus Surgery + adjuvant Gemcitabine/Capecitabine Recruiting
PANACHE01-PRODIGE48 (50) R 168 mFOLFIRINOX + Surgery + adjuvant chemotherapy versus FOLFOX + Surgery + adjuvant chemotherapy versus Surgery + adjuvant chemotherapy Recruiting
ALLIANCE A021806 R 352 mFOLFIRINOX + Surgery versus Surgery + adjuvant mFOLFIRINOX Recruiting
PREOPANC-2 (51) R/BR 375 FOLFIRINOX + Surgery versus Gemcitabine + CRT (Gemcitabine + 36 Gy RT) + Surgery + adjuvant Gemcitabine Completed
PANDAS-PRODIGE- 44 BR 90 mFOLFIRINOX + CRT (capecitabine + 50.4 Gy RT) + Surgery + adjuvant Gemcitabine (or LV5FU) versus mFOLFIRINOX + Surgery + adjuvant Gemcitabine (or LV5FU) Recruiting

R, resectable; BR, borderline resectable; FOLFIRINOX, oxaliplatin, irinotecan, fluorouracil, and leucovorin; mFOLFIRINOX, modified regimen of oxaliplatin, leucovorin, irinotecan, and fluorouracil; chemotherapy, choice at discretion of medical team; LV5FU, infused 5-fluorouracil/folinic acid.

HHS Vulnerability Disclosure